<DOC>
	<DOC>NCT02529488</DOC>
	<brief_summary>The purpose of this study is to investigate visual outcomes and assess safety at 12 months (330-420 days) post bilateral implantation of the AcrySof® IQ PanOptix™ Presbyopia-Correcting IOL.</brief_summary>
	<brief_title>Investigation of AcrySof® IQ PanOptix™ Presbyopia-Correcting Intraocular Lens (IOL) Model TFNT00</brief_title>
	<detailed_description>This study will be conducted in regions where the test article is approved at the time of study start.</detailed_description>
	<mesh_term>Cataract</mesh_term>
	<mesh_term>Presbyopia</mesh_term>
	<criteria>Diagnosis of bilateral cataracts with planned cataract removal by phacoemulsification with a clear cornea incision; Able to comprehend and willing to sign informed consent and complete all required postoperative followup procedures; Clear intraocular media other than cataract in both eyes; Other protocolspecified inclusion criteria may apply. Clinically significant corneal abnormalities including corneal dystrophy, inflammation or edema; Ocular trauma, corneal transplant, retinal conditions, degenerative eye disorders, or color vision deficiencies; Glaucoma (uncontrolled or controlled with medication) or ocular hypertension; Pregnant or lactating; Expected to require ocular surgical or retinal laser treatment; Other protocolspecified exclusion criteria may apply.</criteria>
	<gender>All</gender>
	<minimum_age>22 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>April 2017</verification_date>
</DOC>